If we speculate, that the treatment by anthracyclines results in the restoration of BRCA1 function via secondary mutation or other mechanisms [24, 28], the subsequent use of taxanes is likely to render the benefit similar to the one observed in non-selected BC patients. The gene discussed is BRCA1; the disease is breast cancer.